Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Baccharis halimifolia pollen is an allergenic extract derived from the pollen of the groundsel tree (*Baccharis halimifolia*), a shrub native to the eastern United States. It is primarily used as a diagnostic tool in allergy testing to identify patients with hypersensitivity to this specific pollen, which is a common fall allergen. The extract is administered via skin testing (intradermal or percutaneous) or subcutaneous routes. It works by eliciting a localized IgE-mediated allergic response in sensitized individuals, allowing for the diagnosis of allergic rhinitis or other respiratory allergies triggered by the plant. In addition to diagnostic use, such extracts may be used in subcutaneous immunotherapy (SCIT) to desensitize patients over time.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on baccharis halimifolia pollen.